Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of R130 Oncolytic Virus in Advanced Solid Tumors
NCT05961111Phase 1Recruiting
- Sponsor
- Shanghai Yunying Medical Technology Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R130 in solid tumor (advanced stage), sponsored by Shanghai Yunying Medical Technology Co., Ltd. Primary endpoints: Subject incidence of adverse events up to 6 months, Subject incidence of laboratory abnormalities up to 1 month and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
R130
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05961111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961111.